Eugene serves as Co-Head of Healthcare Investment Banking and U.S. Head of Biotechnology and Specialty Pharmaceuticals, focused on mergers and acquisitions and capital raising transactions. He joined us in 2010 to enhance our emerging therapeutics sector focus, bringing over 19 years of significant life sciences investment banking experience at HSBC, Wells Fargo, and Robertson Stephens. He has advised clients on a wide variety of corporate finance and strategic assignments, including mergers & acquisitions, IPOs, public offerings and private placements of debt and equity securities, PIPEs and LBOs for both public and private companies. Eugene graduated from the Leonard N. Stern School of Business at New York University with an MBA and a degree in Biology from New York University.
Selected Transactions
-
US$112m
Stoke Therapeutics, Inc.
Bookrunner (Follow-On)
-
US$21m
Ocuphire Pharma, Inc.
Joint Agent (Priv Placement)
-
US$41m
Rezolute
Joint Placement Agent (PIPE)
-
£147m
COMPASS Pathways
Lead Manager (IPO)
-
US$85m
Metacrine, Inc.
Lead Manager (IPO)
-
US$350m
Co-lead Manager for Intra-Cellular Therapies on its follow-on offering
Co-lead Manager (Follow-On)
-
US$260m
Seres Therapeutics
Co-Manager (Follow-on)
-
US$125m
Atreca, Inc.
Lead Manager (CMPO)
-
US$200m
Verona Pharma plc
Co-Agent (Private Placement)
